Current and historical daily PE Ratio for Valerio Therapeutics (
) from 1990 to Sep 22 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Valerio Therapeutics stock (FRA:C4X) PE ratio as of Sep 22 2024 is 0.
More Details
Valerio Therapeutics (FRA:C4X) PE Ratio (TTM) Chart
Valerio Therapeutics (FRA:C4X) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1202
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Valerio Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-09-22 | At Loss | 2024-07-22 | At Loss |
| 2024-09-20 | At Loss | 2024-07-19 | At Loss |
| 2024-09-19 | At Loss | 2024-07-18 | At Loss |
| 2024-09-18 | At Loss | 2024-07-17 | At Loss |
| 2024-09-17 | At Loss | 2024-07-16 | At Loss |
| 2024-09-16 | At Loss | 2024-07-15 | At Loss |
| 2024-09-13 | At Loss | 2024-07-12 | At Loss |
| 2024-09-12 | At Loss | 2024-07-11 | At Loss |
| 2024-09-11 | At Loss | 2024-07-10 | At Loss |
| 2024-09-10 | At Loss | 2024-07-09 | At Loss |
| 2024-09-09 | At Loss | 2024-07-08 | At Loss |
| 2024-09-06 | At Loss | 2024-07-05 | At Loss |
| 2024-09-05 | At Loss | 2024-07-04 | At Loss |
| 2024-09-04 | At Loss | 2024-07-03 | At Loss |
| 2024-09-03 | At Loss | 2024-07-02 | At Loss |
| 2024-09-02 | At Loss | 2024-07-01 | At Loss |
| 2024-08-30 | At Loss | 2024-06-28 | At Loss |
| 2024-08-29 | At Loss | 2024-06-27 | At Loss |
| 2024-08-28 | At Loss | 2024-06-26 | At Loss |
| 2024-08-27 | At Loss | 2024-06-25 | At Loss |
| 2024-08-26 | At Loss | 2024-06-24 | At Loss |
| 2024-08-23 | At Loss | 2024-06-21 | At Loss |
| 2024-08-22 | At Loss | 2024-06-20 | At Loss |
| 2024-08-21 | At Loss | 2024-06-19 | At Loss |
| 2024-08-20 | At Loss | 2024-06-18 | At Loss |
| 2024-08-19 | At Loss | 2024-06-17 | At Loss |
| 2024-08-16 | At Loss | 2024-06-14 | At Loss |
| 2024-08-15 | At Loss | 2024-06-13 | At Loss |
| 2024-08-14 | At Loss | 2024-06-12 | At Loss |
| 2024-08-13 | At Loss | 2024-06-11 | At Loss |
| 2024-08-12 | At Loss | 2024-06-10 | At Loss |
| 2024-08-09 | At Loss | 2024-06-07 | At Loss |
| 2024-08-08 | At Loss | 2024-06-06 | At Loss |
| 2024-08-07 | At Loss | 2024-06-05 | At Loss |
| 2024-08-06 | At Loss | 2024-06-04 | At Loss |
| 2024-08-05 | At Loss | 2024-06-03 | At Loss |
| 2024-08-02 | At Loss | 2024-05-31 | At Loss |
| 2024-08-01 | At Loss | 2024-05-30 | At Loss |
| 2024-07-31 | At Loss | 2024-05-29 | At Loss |
| 2024-07-30 | At Loss | 2024-05-28 | At Loss |
| 2024-07-29 | At Loss | 2024-05-27 | At Loss |
| 2024-07-26 | At Loss | 2024-05-24 | At Loss |
| 2024-07-25 | At Loss | 2024-05-23 | At Loss |
| 2024-07-24 | At Loss | 2024-05-22 | At Loss |
| 2024-07-23 | At Loss | 2024-05-21 | At Loss |
Valerio Therapeutics (FRA:C4X) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Valerio Therapeutics
ISIN : FR0010095596
Description
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers